Posts Feed
Comments Feed

« Proposed Mont. Amendment That Would Define Person As Beginning At Fertilization Cleared For Signature GatheringSociety For Assisted Reproductive Technology To Create Egg, Sperm Donor Birth Outcome »

NicOx Announces Pfizer Initiates Phase 2 Clinical Development For PF-03187207 In Japan

Jan 4th 2008Drug InformationClinical Trials

NicOx S.A. (Euronext Paris: COX) announced that Pfizer Inc (NYSE: PFE) has initiated a dose-ranging phase 2 clinical study for PF-03187207 in Japan. PF-03187207 is a new experimental medicine for the treatment of glaucoma, which is currently in an ongoing phase 2 proof-of-concept study in the United States (see press releases of March 28 and 29, 2007).

More: continued here

No Comments »

Trackback URI | Comments RSS

Leave a Reply

You must be logged in to post a comment.

1